Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended September 30, 2005
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Principal products include Aranesp, EPOGEN, Neulasta, NEUPOGEN, and ENBREL (co-promoted with Wyeth). The company operates in one business segment: human therapeutics.
Key Financial Metrics
| Financial Metric (in millions) | 3 Months Ended Sept 30, 2005 |
9 Months Ended Sept 30, 2005 |
9 Months Ended Sept 30, 2004 |
|---|---|---|---|
| Total Revenues | $3,154 | $9,159 | $7,641 |
| Product Sales | $3,047 | $8,854 | $7,199 |
| Operating Income | $1,298 | $3,747 | $2,429 |
| Net Income | $967 | $2,850 | $1,674 |
| Diluted EPS | $0.77 | $2.26 | $1.28 |
| Operating Cash Flow (9mo) | N/A | $3,782 | $2,587 |
| Cash & Marketable Securities | $5,551 | $5,551 | $5,808 (Dec 31, 2004) |
| Total Debt (Current + Long-term) | $3,952 | $3,952 | $5,110 (Dec 31, 2004) |
Note: Debt figures include $1.754 billion in current convertible notes and $2.198 billion in other long-term debt as of Sept 30, 2005.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 16% for the quarter and 20% for the nine-month period compared to 2004. Product sales grew 19% (quarter) and 23% (nine months), driven primarily by Aranesp, ENBREL, and Neulasta.
- Profitability Surge: Net income increased significantly (310% for the quarter, 70% for nine months). This improvement is largely attributable to the absence of a $554 million non-recurring charge for acquired in-process research and development (IPR&D) from the Tularik acquisition recorded in the same period in 2004.
- Operating Expenses: Operating expenses decreased 16% for the quarter and increased 4% for the nine months. The quarter-over-quarter decrease was due to the lack of the Tularik IPR&D write-off. R&D expenses increased 12% (quarter) and 17% (nine months) due to higher staff costs and clinical trial ramp-ups (e.g., denosumab).
- Legal Settlements: A $49 million legal settlement expense was recorded in the second quarter of 2005 (included in the nine-month total), primarily related to patent proceedings. No such expense was recorded in the third quarter of 2005.
- Debt Restructuring: In March 2005, Amgen repurchased approximately 40% of its outstanding convertible notes for $1.175 billion. In May and August 2005, the remaining notes were exchanged for "Modified Convertible Notes" with different conversion and put terms.
Guidance, Outlook, and Risks
- Outlook: Management expects operating expenses to increase in the fourth quarter of 2005 in absolute dollars and as a percentage of sales due to continued R&D investment and support for principal products. Capital expenditures for 2005 are estimated at approximately $1.0 billion.
- Reimbursement Risks (MMA): The Medicare Modernization Act (MMA) has lowered reimbursement rates for key products (Aranesp, Neulasta, NEUPOGEN, EPOGEN) in 2005. While sales were not significantly impacted in the first three quarters due to the "2005 Demonstration Project," management anticipates potential negative impacts in 2006 due to reduced physician service payments and changes in the demonstration project criteria.
- Patent Expirations: The principal European patent for erythropoietin expired in December 2004, and the principal European patent for G-CSF expires in August 2006. Management expects follow-on biologics to enter the EU market by the end of 2006, increasing competition.
- Manufacturing Dependencies: Significant reliance on third-party manufacturers (e.g., Boehringer Ingelheim for ENBREL bulk supply) and single-source suppliers for raw materials poses supply chain risks. The Puerto Rico facility is critical for formulation, fill, and finish of most products.
- Legal Proceedings: Ongoing litigation includes Average Wholesale Price (AWP) cases filed by various states and a new antitrust suit filed by Ortho Biotech regarding discounting practices. Amgen also filed a patent infringement suit against F. Hoffmann-LaRoche Ltd.
Investor Verification Checklist
- Reimbursement Impact: Verify the actual impact of the 2006 Medicare Physician Fee Schedule and the new "2006 Demonstration Project" on Q4 2005 and 2006 sales volumes for Aranesp and EPOGEN.
- Convertible Note Terms: Confirm the specific conversion triggers and cash settlement requirements for the "Modified Convertible Notes" issued in 2005, particularly regarding the March 2006 put option.
- ENBREL Supply Chain: Monitor production yields and capacity at the Rhode Island facility and third-party partner Boehringer Ingelheim to ensure no supply interruptions for ENBREL.
- Legal Exposure: Track the status of the AWP litigation and the Ortho Biotech antitrust suit for potential future settlements or injunctions.
- Stock Repurchases: Note that $2.775 billion remains available under the stock repurchase program as of September 30, 2005.